Global Autoimmune Disease Diagnostics Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The global autoimmune disease diagnostics market encompasses laboratory testing for over 80 recognized autoimmune conditions, including rheumatoid arthritis, lupus, and thyroid disorders. Valued at approximately $6.17 billion in 2025, the market is on a trajectory of steady expansion driven by increasing disease prevalence and technological advancement in diagnostic methodologies.

• •Covers laboratory tests including ELISA, immunofluorescence assays, and immunoblotting
• •Rising awareness and earlier disease detection expanding patient pools globally
• •Recurring assay kit sales and confirmatory testing provide stable revenue streams

Increasing prevalence of autoimmune disorders, particularly among women and aging populations, is a primary catalyst for market expansion. Greater healthcare spending and improved access to diagnostic facilities in emerging economies are further accelerating adoption rates.

• •Estimated 5-8% of global population affected by autoimmune conditions
• •Growing geriatric demographic at higher risk for autoimmune dysfunction
• •Favorable reimbursement policies in developed markets supporting testing volume

The market is segmented by product type, including consumables, assay kits, and instruments, with test categories covering systemic, organ-specific, and endocrine autoimmune disorders. North America leads in market share due to advanced healthcare infrastructure and high disease awareness, while the Asia-Pacific region is projected to grow the fastest.

• •North America commands approximately 40% of global market share
• •Asia-Pacific emerging as fastest-growing region driven by improving healthcare access
• •Common test types include rheumatoid factor, ANA, and anti-CCP assays

What are the recent trends and outlook?

Emerging trends include the integration of artificial intelligence for result interpretation, development of biomarker-based tests for earlier diagnosis, and expansion of decentralized testing options. With a projected 7.0% annual growth rate, the market is expected to continue its upward trajectory through the decade.

• •Multiplex assay platforms enabling simultaneous detection of multiple autoantibodies
• •Growing emphasis on personalized medicine driving demand for comprehensive profiling
• •Expansion of CLIA-waived point-of-care tests increasing accessibility in primary care settings